← All trials
NCT05164549
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2019
- Primary completion
- May 31, 2022
- Completion date
- Dec 1, 2022
- First posted
- Dec 20, 2021
- Last posted
- Dec 20, 2021
- Enrollment
- 604
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- University of BirminghamCollaborator
- University of DundeeCollaborator
- South London and Maudsley NHS Foundation TrustOverall official - principal investigator
- South London and Maudsley NHS Foundation TrustCollaborator
- Bangor UniversityCollaborator
- University of ManchesterCollaborator
- Northumberland, Tyne and Wear NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.